<Summary id="CDR0000062680" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Treatment for children with brain and spinal cord tumors is based on histology and location within the brain. This summary provides links to information, including treatment, for these tumors.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/brain/hp/child-brain-treatment-pdq">Childhood Brain and Spinal Cord Tumors   Summary Index (PDQ®): Treatment</SummaryURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000041539">childhood brain tumor</TermRef></MainTopics><SummaryAbstract><Para id="_420">This PDQ cancer information summary for health professionals provides links to comprehensive, peer-reviewed, evidence-based information about the treatment of childhood brain and spinal cord tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_421">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>childhood brain tumor</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Brain and Spinal Cord Tumors Summary Index (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Brain  and Spinal Cord Tumors Summary Index (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Brain  and Spinal Cord Tumors Summary Index</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000041539">childhood brain tumor</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Childhood Brain and Spinal Cord Tumors</Title><Para id="_441">Primary brain tumors are a diverse group of diseases that together constitute the most common solid tumor of childhood. The Central Brain Tumor Registry of the United States (CBTRUS) estimates that approximately 4,300 U.S. children are diagnosed each year.<Reference refidx="1"/></Para><Para id="_442"> Brain tumors are classified by histology, but tumor location and extent of spread are also important factors that affect treatment and prognosis. Immunohistochemical analysis, cytogenetic and molecular genetic findings, and measures of proliferative activity are increasingly used in tumor diagnosis and classification.<Reference refidx="2"/></Para><ReferenceSection><Citation idx="1" PMID="24137015">Ostrom QT, Gittleman H, Farah P, et al.: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 (Suppl 2): ii1-56, 2013.</Citation><Citation idx="2" PMID="27157931">Louis DN, Perry A, Reifenberger G, et al.: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6): 803-20, 2016.</Citation></ReferenceSection></SummarySection><SummarySection id="_397"><Title>Type of Childhood Brain and Spinal Cord Tumors</Title><Para id="_448">For information about the type of childhood brain and spinal cord tumor and its related PDQ summary, see the table below. If a tumor type is not listed, a corresponding PDQ treatment summary is not available.</Para><Table id="_443"><Title>CNS Tumor Type, Pathological Subtype, and Its Related PDQ Treatment Summary</Title><TGroup Cols="3"><ColSpec ColName="col0" ColNum="1" ColWidth="33.33%"/><ColSpec ColName="col1" ColNum="2" ColWidth="33.33%"/><ColSpec ColName="col2" ColNum="3" ColWidth="33.33%"/><THead><Row><entry>Tumor Type (Based on the 2021 WHO  Classification)<Superscript>a</Superscript></entry><entry>Pathological Subtype  (Based on the 2021 WHO  Classification)<Superscript>a</Superscript></entry><entry>Related PDQ Treatment Summary</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col0">CNS = central nervous system; NEC = not elsewhere classified; NOS = not otherwise specified; WHO = World Health Organization.</entry></Row><Row><entry NameEnd="col2" NameSt="col0"><Superscript>a</Superscript>WHO classification adapted from Louis et al.<Reference refidx="1"/></entry></Row></TFoot><TBody><Row><entry MoreRows="3"><Strong>Pediatric-type diffuse high-grade gliomas</Strong></entry><entry>Diffuse pediatric-type high-grade glioma, H3-wild type and <GeneName>IDH</GeneName>-wild type</entry><entry MoreRows="3"><SummaryRef href="CDR0000614165" url="/types/brain/hp/child-astrocytoma-glioma-treatment-pdq">Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment</SummaryRef><SummaryRef href="CDR0000614165" url="/types/brain/hp/child-astrocytoma-glioma-treatment-pdq"/> </entry></Row><Row><entry>Diffuse midline glioma, H3 K27-altered</entry></Row><Row><entry>Diffuse hemispheric glioma, H3 G34-mutant</entry></Row><Row><entry>Infant-type hemispheric glioma</entry></Row><Row><entry MoreRows="5"><Strong>Circumscribed astrocytic gliomas</Strong></entry><entry>Pilocytic astrocytoma</entry><entry MoreRows="5"><SummaryRef href="CDR0000614165" url="/types/brain/hp/child-astrocytoma-glioma-treatment-pdq">Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment</SummaryRef></entry></Row><Row><entry>High-grade astrocytoma with piloid features</entry></Row><Row><entry>Subependymal giant cell astrocytoma</entry></Row><Row><entry>Pleomorphic xanthoastrocytoma</entry></Row><Row><entry>Choroid glioma</entry></Row><Row><entry>Astroblastoma, <GeneName>MN1</GeneName>-altered</entry></Row><Row><entry MoreRows="9"><Strong>Ependymal tumors</Strong></entry><entry>Subependymoma</entry><entry MoreRows="9"><SummaryRef href="CDR0000062843" url="/types/brain/hp/child-ependymoma-treatment-pdq">Childhood Ependymoma Treatment</SummaryRef></entry></Row><Row><entry>Myxopapillary ependymoma</entry></Row><Row><entry>Supratentorial ependymoma, NOS</entry></Row><Row><entry>Supratentorial ependymoma, <GeneName>ZFTA</GeneName> fusion–positive</entry></Row><Row><entry>Supratentorial ependymoma, <GeneName>YAP1</GeneName> fusion–positive</entry></Row><Row><entry>Posterior fossa ependymoma, NOS</entry></Row><Row><entry>Posterior fossa group A (PFA) ependymoma</entry></Row><Row><entry>Posterior fossa group B (PFB) ependymoma</entry></Row><Row><entry>Spinal ependymoma, NOS</entry></Row><Row><entry>Spinal ependymoma, <GeneName>MYCN</GeneName>-amplified</entry></Row><Row><entry MoreRows="3"><Strong>Pediatric-type diffuse low-grade glioma</Strong></entry><entry>Diffuse astrocytoma, <GeneName>MYB</GeneName>- or <GeneName>MYBL1</GeneName>-altered</entry><entry MoreRows="3"><SummaryRef href="CDR0000614165" url="/types/brain/hp/child-astrocytoma-glioma-treatment-pdq">Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment</SummaryRef></entry></Row><Row><entry>Angiocentric glioma </entry></Row><Row><entry>Polymorphous low-grade neuroepithelial tumor of the young </entry></Row><Row><entry>Diffuse low-grade glioma, MAPK pathway-altered </entry></Row><Row><entry MoreRows="14"><Strong>Glioneuronal and neuronal tumors</Strong></entry><entry>Dysembryoplastic neuroepithelial tumor</entry><entry MoreRows="14"><SummaryRef href="CDR0000614165" url="/types/brain/hp/child-astrocytoma-glioma-treatment-pdq">Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment</SummaryRef></entry></Row><Row><entry>Ganglioglioma</entry></Row><Row><entry>Gangliocytoma</entry></Row><Row><entry>Desmoplastic infantile ganglioglioma</entry></Row><Row><entry>Desmoplastic infantile astrocytoma</entry></Row><Row><entry>Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (provisional entity)</entry></Row><Row><entry>Papillary glioneuronal tumor</entry></Row><Row><entry>Rosette-forming glioneuronal tumor</entry></Row><Row><entry>Myxoid glioneuronal tumor</entry></Row><Row><entry>Diffuse leptomeningeal glioneuronal tumor</entry></Row><Row><entry>Multinodular and vacuolating neuronal tumor</entry></Row><Row><entry>Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)</entry></Row><Row><entry>Extraventricular neurocytoma</entry></Row><Row><entry>Cerebellar liponeurocytoma</entry></Row><Row><entry>Central neurocytoma</entry></Row><Row><entry><Strong>Tumors of the pineal region</Strong></entry><entry>Pineoblastoma</entry><entry><SummaryRef href="CDR0000548358" url="/types/brain/hp/child-cns-embryonal-treatment-pdq">Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment</SummaryRef></entry></Row><Row><entry MoreRows="12"><Strong>Embryonal tumors</Strong></entry><entry>Medulloblastoma, <GeneName>WNT</GeneName>-activated</entry><entry MoreRows="11"><SummaryRef href="CDR0000548358" url="/types/brain/hp/child-cns-embryonal-treatment-pdq">Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment</SummaryRef></entry></Row><Row><entry>Medulloblastoma, SHH-activated and <GeneName>TP53</GeneName>-mutant; Medulloblastoma, SHH-activated and <GeneName>TP53</GeneName>-wildtype</entry></Row><Row><entry>Medulloblastoma, non-<GeneName>WNT</GeneName>/non-SHH </entry></Row><Row><entry>Medulloblastoma, histologically defined</entry></Row><Row><entry>Desmoplastic nodular medulloblastoma</entry></Row><Row><entry>Medulloblastoma with extensive nodularity</entry></Row><Row><entry>Large cell medulloblastoma</entry></Row><Row><entry>Anaplastic medulloblastoma</entry></Row><Row><entry>Embryonal tumor with multilayered rosettes, <GeneName>C19MC</GeneName>-altered</entry></Row><Row><entry>CNS tumor with <GeneName>BCOR</GeneName> internal tandem duplication</entry></Row><Row><entry>CNS neuroblastoma, <GeneName>FOXR2</GeneName>-activated</entry></Row><Row><entry>CNS embryonal tumor, NEC/NOS</entry></Row><Row><entry>Atypical teratoid/rhabdoid tumor</entry><entry><SummaryRef href="CDR0000587224" url="/types/brain/hp/child-cns-atrt-treatment-pdq">Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment</SummaryRef></entry></Row><Row><entry MoreRows="7"><Strong>Germ cell tumors</Strong></entry><entry>Germinoma</entry><entry MoreRows="7"><SummaryRef href="CDR0000712041" url="/types/brain/hp/child-cns-germ-cell-treatment-pdq">Childhood Central Nervous System Germ Cell Tumors Treatment</SummaryRef></entry></Row><Row><entry>Embryonal carcinoma</entry></Row><Row><entry>Yolk sac tumor</entry></Row><Row><entry>Choriocarcinoma</entry></Row><Row><entry>Mature teratoma</entry></Row><Row><entry>Immature teratoma</entry></Row><Row><entry>Teratoma with somatic-type malignancy</entry></Row><Row><entry>Mixed germ cell tumor</entry></Row><Row><entry MoreRows="1"><Strong>Tumors of the sellar region</Strong></entry><entry>Adamantinomatous craniopharyngioma</entry><entry MoreRows="1"><SummaryRef href="CDR0000589150" url="/types/brain/hp/child-cranio-treatment-pdq">Childhood Craniopharyngioma Treatment</SummaryRef></entry></Row><Row><entry>Papillary craniopharyngioma</entry></Row></TBody></TGroup></Table><ReferenceSection><Citation idx="1" PMID="34185076">Louis DN, Perry A, Wesseling P, et al.: The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23 (8): 1231-1251, 2021.</Citation></ReferenceSection></SummarySection><SummarySection id="_112"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (12/19/2023)</Title><Para id="_113">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_449">This summary was comprehensively reviewed and extensively revised.</Para><Para id="_450">This summary was renamed from Childhood Brain and Spinal Cord Tumors Treatment Overview.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062680#_AboutThis_1" url="/types/brain/hp/child-brain-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood brain and spinal cord tumors. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Brain and Spinal Cord Tumors Summary Index are:</Para><ItemizedList Style="bullet"><ListItem>Kenneth J. Cohen, MD, MBA (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital)</ListItem><ListItem>Louis S. Constine, MD (James P. Wilmot Cancer Center at University of Rochester Medical Center)</ListItem><ListItem>Roger J. Packer, MD (Children's National Hospital)</ListItem><ListItem>D. Williams Parsons, MD, PhD (Texas Children's Hospital)</ListItem><ListItem>Malcolm A. Smith, MD, PhD (National Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Brain and Spinal Cord Tumors Summary Index. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/brain/hp/child-brain-treatment-pdq">https://www.cancer.gov/types/brain/hp/child-brain-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389453]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2023-12-19</DateLastModified></Summary>
